cis-AGB1|CAS 2776190-80-6 |DC Chemicals

Cas No.:	2776190-80-6
Chemical Name:	BromoTag-cis-agb1
SMILES:	ClC1=CC=C(C2=N[C@@H]([C@H](C(OCCOCCOCCOCC(N[C@H](C(N3C[C@H](C[C@H]3C(NCC4=CC=C(C5=C(N=CS5)C)C=C4)=O)O)=O)C(C)(C)C)=O)=O)CC)C6=NN=C(C)N6C7=C2C(C)=C(S7)C)C=C1
Formula:	C₅₁H₆₃ClN₈O₉S₂
M.Wt:	1031.68
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC67098	cis-AGB1	Cis-AGB1 is a negative control for AGB1 . Exhibits no significant VHL binding affinity.
DC67029	KT-413	KT-413 (example I-3) is a potent IRAK degrader.
DC65810	KT-333	KT-333 is a first-in-class molecular glue that induces selective degradation of STAT3 via the ubiquitin-proteasome system by simultaneously engaging STAT3 and the VHL E3 ligase. This novel mechanism enables potent STAT3 depletion with minimal off-target effects, demonstrating strong anti-tumor activity in hematologic malignancies.
DC60530	BTK-IN-24(NX-5948)	NX-5948,be also known as BTK-IN-24,is an oral BTK degrader.
DC60510	Iso-A11B5C1	Iso-A11B5C1 is an ionizable lipid. The iso-A11B5C1 LNP demonstrates a high level of muscle-specific mRNA delivery efficiency. exhibiting transfection efficiency comparable to the commercially available lipid SM-102, while considerably reducing inadvertent mRNA expression in main organs such as the liver and spleen.Additionally, study results show that intramuscular administration of mRNA formulated with iso-A11B5C1 LNP caused potent cellular immune responses, even with limited expression observed in lymph nodes.
DC65680	Lipid 2-10	Lipid 2-10, an ionizable lipid with a pKa of 6.16, is utilized in the formulation of lipid nanoparticles (LNPs) featuring a bilayer structure.
DC65324	NX-2127	NX-2127 is a potent, selective, and orally bioavailable BTK degrader with Kd of 18 nM (for WT BTK), 45 nM (BTK C481S), 18 nM (BTK T474I), 44 nM (BTK M437R), 97 nM (BTK V416L), and 88 nM (BTK L528W), respectively. NX-2127 efficiently engages the intracellular ubiquitin-proteasome system to simultaneously bind both BTK and the CRBN E3 ubiquitin ligase complex, inducing polyubiquitination and proteasome-dependent degradation of BTK, IKZF1, and IKZF3.
DC65210	CFT1946	CFT1946 is an orally active and selective target ligand for BRAF kinase.
DC65207	CFT-8634	CFT8634 is an oral activity degrader targeting BRD9 extracted from patent WO2021178920A1 compound 174. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors.
DC60447	ARV-766	ARV-766 is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations[1].